A Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

Safa AhmadianKate M JohnsonJoseph Khoa HoDon D SinLarry D LyndMark HarrisonJ Mark FitzGerald

Published in: Annals of the American Thoracic Society (2023)

Add-on azithromycin is cost-effective in patients with a recent history of exacerbations at commonly accepted willingness-to-pay thresholds of $50,000-$100,000 / QALY. Guidelines should consider recommending add-on azithromycin for patients who had at least one moderate or severe exacerbation in the past year, albeit more information about treatment efficacy would strengthen this recommendation.

Keyphrases

chronic obstructive pulmonary disease
cystic fibrosis
respiratory failure
liver failure
early onset
high intensity
clinical practice
health insurance
intensive care unit
combination therapy
hepatitis b virus
mechanical ventilation